Form 4: Catalyst Pharmaceuticals Director Charles B. O'Keeffe Reports Stock Unit Vesting

Director Charles B. O'Keeffe reports the vesting of restricted stock units in Catalyst Pharmaceuticals, resulting in the acquisition of 1,333 shares.

Summary

• On December 27, 2024, Charles B. O'Keeffe, a director of Catalyst Pharmaceuticals, Inc. (CPRX), had 1,333 restricted stock units vest.
• These units convert into common stock on a 1:1 basis.
• Following the transaction, O'Keeffe directly owns 728,470 shares of common stock and 212,274 derivative securities.
• The vested shares were delivered on December 27, 2024.
• The restricted stock units vest in three equal tranches annually on December 27, 2023, December 27, 2024, and December 27, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a routine transaction related to executive compensation. It doesn't inherently indicate positive or negative prospects for the company.

Positives

• The vesting of restricted stock units indicates continued alignment of the director's interests with those of the shareholders.

Future Outlook

The final tranche of restricted stock units is scheduled to vest on December 27, 2025.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, in their own company's stock. This allows investors to monitor insider activity, which can sometimes provide insights into management's view of the company's prospects.

Comparison to Industry Standards

• Comparing O'Keeffe's holdings and transactions to those of directors at similar-sized pharmaceutical companies can provide context.
• For example, directors at companies like BioCryst Pharmaceuticals or Amicus Therapeutics also receive stock-based compensation, and their Form 4 filings can be compared to assess relative levels of insider ownership and activity.
• Analyzing the vesting schedules and the size of equity grants relative to company performance can also offer valuable insights.

Stakeholder Impact

• The vesting of stock units has a minor dilutive effect on existing shareholders.
• It also incentivizes the director to act in the best interests of the shareholders.

Key Dates